Podcast - Episode 51 "Buy High. Sell Low."
Subscribe to the podcast to get the fatties to buy the weight loss shots.
00:00:00 Novo Nordisk $NVO (+1.68%)
00:29:00 Eli Lilly $LLY0
00:38:00 Nvidia HS4PHR $NVDA (+4.8%)
00:50:00 AMD $AMD (+6.24%)
01:05:00 Intel $INTC (+3.07%)
01:25:00 Gold $4GLD (+0.95%)
$ABX (+0.19%)
$IGLN (+0.96%)
$EWG2 (+1.25%)
Spotify
https://open.spotify.com/episode/5lxqJBmJJrom4MFGte2FtU?si=R1DfxZG9T82P1SDbYS3zcQ
YouTube
Apple Podcast
The price target is $865.62 and the stock is covered by 27 analysts.
Buy
21
Hold
6
Sell
0
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
